Subtotal gastrectomy or 'en principle' total gastrectomy in cancer of the lower half of the stomach

F. Bozzetti, G. Bonfanti, L. Gennari

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: There is still a matter of controversy whether a subtotal gastrectomy has the same therapeutic potential as a total gastrectomy in distal gastric cancer. Whether all or a subgroup of patients can benefit from total gastrectomy can be answered only by a randomized trial. Method: We therefore assembled a prospective randomized multi-institutional trial which has so far randomized 400 patients for total or subtotal gastrectomy and second level lymphadenectomy. Material: Patients with gastric carcinoma of the lower half of the stomach are eligible unless one of the following conditions exists: Age over 75 years, previous malignant neoplasia except skin cancer, previous gastric resection, high surgical risk, tumor located at less than six centimeters from cardia, tumors not radically resectable. Results: The accrual of patients is still in progress. The available results concern the mortality rate that is higher after total gastrectomy but not statistically different from subtotal resection.

Original languageEnglish
Pages (from-to)84-91
Number of pages8
JournalOncology Research and Treatment
Volume15
Issue number2
DOIs
Publication statusPublished - 1992

Fingerprint

Gastrectomy
Stomach
Neoplasms
Stomach Neoplasms
Cardia
Skin Neoplasms
Lymph Node Excision
Carcinoma
Mortality
Therapeutics

Keywords

  • Gastric cancer
  • Nutritional sequelae
  • Subtotal gastrectomy
  • Total gastrectomy

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Subtotal gastrectomy or 'en principle' total gastrectomy in cancer of the lower half of the stomach. / Bozzetti, F.; Bonfanti, G.; Gennari, L.

In: Oncology Research and Treatment, Vol. 15, No. 2, 1992, p. 84-91.

Research output: Contribution to journalArticle

@article{33fbbef2176049298e4870e0160f321b,
title = "Subtotal gastrectomy or 'en principle' total gastrectomy in cancer of the lower half of the stomach",
abstract = "Background: There is still a matter of controversy whether a subtotal gastrectomy has the same therapeutic potential as a total gastrectomy in distal gastric cancer. Whether all or a subgroup of patients can benefit from total gastrectomy can be answered only by a randomized trial. Method: We therefore assembled a prospective randomized multi-institutional trial which has so far randomized 400 patients for total or subtotal gastrectomy and second level lymphadenectomy. Material: Patients with gastric carcinoma of the lower half of the stomach are eligible unless one of the following conditions exists: Age over 75 years, previous malignant neoplasia except skin cancer, previous gastric resection, high surgical risk, tumor located at less than six centimeters from cardia, tumors not radically resectable. Results: The accrual of patients is still in progress. The available results concern the mortality rate that is higher after total gastrectomy but not statistically different from subtotal resection.",
keywords = "Gastric cancer, Nutritional sequelae, Subtotal gastrectomy, Total gastrectomy",
author = "F. Bozzetti and G. Bonfanti and L. Gennari",
year = "1992",
doi = "10.1159/000217341",
language = "English",
volume = "15",
pages = "84--91",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Subtotal gastrectomy or 'en principle' total gastrectomy in cancer of the lower half of the stomach

AU - Bozzetti, F.

AU - Bonfanti, G.

AU - Gennari, L.

PY - 1992

Y1 - 1992

N2 - Background: There is still a matter of controversy whether a subtotal gastrectomy has the same therapeutic potential as a total gastrectomy in distal gastric cancer. Whether all or a subgroup of patients can benefit from total gastrectomy can be answered only by a randomized trial. Method: We therefore assembled a prospective randomized multi-institutional trial which has so far randomized 400 patients for total or subtotal gastrectomy and second level lymphadenectomy. Material: Patients with gastric carcinoma of the lower half of the stomach are eligible unless one of the following conditions exists: Age over 75 years, previous malignant neoplasia except skin cancer, previous gastric resection, high surgical risk, tumor located at less than six centimeters from cardia, tumors not radically resectable. Results: The accrual of patients is still in progress. The available results concern the mortality rate that is higher after total gastrectomy but not statistically different from subtotal resection.

AB - Background: There is still a matter of controversy whether a subtotal gastrectomy has the same therapeutic potential as a total gastrectomy in distal gastric cancer. Whether all or a subgroup of patients can benefit from total gastrectomy can be answered only by a randomized trial. Method: We therefore assembled a prospective randomized multi-institutional trial which has so far randomized 400 patients for total or subtotal gastrectomy and second level lymphadenectomy. Material: Patients with gastric carcinoma of the lower half of the stomach are eligible unless one of the following conditions exists: Age over 75 years, previous malignant neoplasia except skin cancer, previous gastric resection, high surgical risk, tumor located at less than six centimeters from cardia, tumors not radically resectable. Results: The accrual of patients is still in progress. The available results concern the mortality rate that is higher after total gastrectomy but not statistically different from subtotal resection.

KW - Gastric cancer

KW - Nutritional sequelae

KW - Subtotal gastrectomy

KW - Total gastrectomy

UR - http://www.scopus.com/inward/record.url?scp=0026566250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026566250&partnerID=8YFLogxK

U2 - 10.1159/000217341

DO - 10.1159/000217341

M3 - Article

AN - SCOPUS:0026566250

VL - 15

SP - 84

EP - 91

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 2

ER -